Table 2 Summary of study characteristics
Author | Year | Study design | Dx | Sample sizes | Method of analysis | |
|---|---|---|---|---|---|---|
ME/CFS/SEID | HCs | |||||
Armstrong et al. | 2015 | Observational case–control | Canadian criteria | 34 | 25 | NMR spectroscopy |
Billing-Ross et al. | 2016 | Observational case–control | Fukuda criteria | 193 | 196 | Illumina sequencing |
Booth et al. | 2012 | Observational case–control | Fukuda criteria | 138 | 53 | ATP profile test |
Castro-Marrero et al. | 2013 | Observational case–control | Fukuda criteria | 23 | 15 | Western blot bioluminescence assay |
Germain et al. | 2017 | Observational case–control | Fukuda criteria IOM 2015 | 17 | 15 | Mass spectrometry |
Light et al. | 2013 | Observational case–control | Fukuda criteria | 39 | 22 | Real time QPCR |
Maes et al. | 2009 | Observational case–control | Fukuda criteria | 58 | 22 | High Performance Liquid Chromatography |
Mandarano et al. | 2019 | Observational case–control | Canadian criteria | 53 | 45 | Seahorse XFe96, Flow cytometry, Confocal microscopy |
Missailidis et al. | 2020A | Observational case–control | Canadian criteria | 51 | 22 | MitoTracker Green FM, Seahorse XFe24 (mitochondrial stress test) |
Missailidis et al. | 2020B | Observational case–control | Canadian criteria | 51 | 22 | Seahorse XFe24 (mitochondrial stress test), XF Glycolysis stress test |
Naviaux et al. | 2016 | Observational case–control | Canadian criteria Fukuda criteria IOM 2015 | 45 | 39 | Hydrophilic interaction liquid chromatography, electrospray ionization, and tandem mass spectrometry |
Nguyen et al. | 2016 | Observational case–control | Fukuda criteria | 17 | 19 | Flow cytometry |
Nguyen et al. | 2019 | Observational case–control | Fukuda criteria International Consensus criteria | 6 | 6 | Seahorse XFp |
Plioplys and Plioplys | 1995 | Observational case–control | Fukuda criteria | 15 | 15 | Electron microscopy |
Shungu et al. | 2012 | Observational case–control | Fukuda criteria | 15 | 13 | Magnetic resonance spectroscopy |
Sweetman et al. | 2019 | Observational case–control | Canadian criteria | 10 | 10 | RNA sequencing |
Tomas et al. | 2017 | Observational case–control | Fukuda criteria | 52 | 35 | Seahorse XFp |
Venter et al. | 2019 | Observational case–control | Fukuda criteria | UK: 89 moderate, 29 severe RSA: 143 moderate | UK: 64 RSA:98 | DNA sequencing |
Yamano et al. | 2016 | Observational case–control | Fukuda criteria | Training: 47 Validation: 20 | Training: 46 Validation: 20 | Agilent CE capillary electrophoresis system |